TGF-beta signaling—specifically transforming growth factor-beta 1 (TGF-β1)—is the primary molecular driver of acne scar formation. When this signaling pathway becomes dysregulated after an acne lesion heals, it triggers excessive collagen production and aberrant repair processes in the dermis, leading to the permanent indentations, raised bumps, and discolored marks that characterize acne scars. Consider what happens during normal wound healing: the body produces some TGF-β1 to trigger repair. But in people prone to acne scarring, this signaling cascade continues unchecked, pushing fibroblasts and myofibroblasts into overdrive, piling collagen onto collagen long after healing should have stopped.
This article explains how TGF-beta signaling works at the cellular level, why dysregulation causes scarring, and what treatments target this pathway to prevent or reduce scar formation. The significance of understanding TGF-beta’s role extends beyond basic biology—it’s reshaping how dermatologists approach scar prevention and treatment. Rather than viewing scars as inevitable consequences of severe acne, researchers now recognize they result from specific molecular failures that can potentially be intercepted. This means future treatments may focus on modulating TGF-beta signaling during and after acne healing, rather than waiting years and then attempting to physically remove or resurface scar tissue.
Table of Contents
- How Does TGF-Beta Control Collagen Production in Acne Scars?
- The Role of Fibroblast Proliferation and microRNA-21 in Acne Scar Development
- Matrix Metalloproteinases, Tissue Inhibitors, and the Breakdown of Dermal Structure
- TGF-Beta Isoforms—Why TGF-β3 Holds Promise While TGF-β1 Drives Fibrosis
- How Dysregulation Transforms Normal Healing Into Excessive Scarring
- Botulinum Toxin as a TGF-Beta Pathway Modulator
- Pharmacological Intervention—Losartan and Beyond
- Conclusion
How Does TGF-Beta Control Collagen Production in Acne Scars?
The TGF-β/Smad signaling pathway is the classical molecular mechanism controlling collagen synthesis in fibroblasts and myofibroblasts—the cells responsible for laying down structural proteins in skin. When TGF-β1 binds to its receptor on these cells, it activates a cascade of intracellular proteins called Smads, which travel to the cell nucleus and activate genes that code for collagen types I and III. Under normal circumstances, this is beneficial—it rebuilds tissue after injury. However, in acne scars, sustained and excessive TGF-β1 activation causes these fibroblasts to remain hyperactive for months or years, continuously churning out collagen even when the lesion has healed and tissue repair is complete.
This sustained overactivation explains why some acne scars remain firm and raised (hypertrophic scars) or sunken (atrophic scars). The distinction matters: hypertrophic scars result from too much collagen being deposited faster than the body can organize it, while atrophic scars result from insufficient collagen rebuilding or later collagen breakdown. Both involve TGF-β dysregulation, but in different ways—excessive TGF-β1 in hypertrophic scarring, and complex dysregulation of collagen-degrading enzymes in atrophic scarring. Understanding this difference is crucial because treatments targeting the TGF-β pathway may work better for one scar type than the other.
The Role of Fibroblast Proliferation and microRNA-21 in Acne Scar Development
TGF-β1 doesn’t just increase collagen production—it also promotes the proliferation and transdifferentiation of fibroblasts into myofibroblasts, a more aggressive cell type that produces even more collagen and contractile proteins. One key mechanism involves microRNA-21 (miR-21), a small regulatory RNA molecule that TGF-β1 upregulates. When miR-21 levels rise, they suppress genes that would normally slow down fibroblast activity, effectively removing the brakes on scar formation. This microRNA pathway accelerates collagen deposition and maintains the scar-producing phenotype of fibroblasts for extended periods.
The practical implication here is important: targeting TGF-β1 alone may be insufficient to fully reverse acne scarring if miR-21 levels remain elevated. Some emerging treatments attempt to simultaneously block TGF-β signaling and suppress miR-21 expression, but these dual-target approaches are still largely experimental. However, if a treatment addresses only one part of this pathway—say, inhibiting TGF-β without reducing miR-21—the fibroblasts may continue their scar-producing behavior through alternative signaling routes, limiting treatment efficacy. This explains why some patients show only partial improvement with single-target therapies.
Matrix Metalloproteinases, Tissue Inhibitors, and the Breakdown of Dermal Structure
Alongside excessive collagen production, acne scar formation involves dysregulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). MMPs are enzymes that break down collagen and other structural proteins in the skin; TIMPs inhibit MMPs. The healthy skin maintains a balanced ratio—enough MMP activity to remove old or misaligned collagen, enough TIMP activity to prevent excessive degradation. But in acne scarring, TGF-β1 dysregulation skews this balance.
Overactivated fibroblasts produce excessive TIMPs and insufficient MMPs, creating a one-way street: collagen accumulates without being remodeled or removed, and the dermal structure becomes permanently disorganized. This imbalance explains why time alone doesn’t always improve acne scars—the body’s natural collagen-remodeling machinery remains broken. A scar formed five years ago has likely fossilized into a stable (but unwanted) collagen configuration. This is why treatments like microneedling or laser resurfacing can help: they deliberately create injury to trigger a new round of wound healing with, hopefully, better-balanced MMP/TIMP activity. However, without addressing the underlying TGF-β dysregulation, even aggressive resurfacing may simply trigger another cycle of excessive scarring in some individuals.
TGF-Beta Isoforms—Why TGF-β3 Holds Promise While TGF-β1 Drives Fibrosis
Not all TGF-beta molecules are created equal. TGF-β1 is the primary mediator of fibrosis and excessive collagen deposition in adult wound healing. But TGF-β3, a different isoform of the same protein family, promotes scarless healing in fetal wounds and reduces scarring in adults when deliberately introduced during wound repair. This distinction is crucial because it reveals that scar formation isn’t simply a consequence of wound healing—it’s a consequence of the wrong type of wound healing signaling.
Fetal skin heals without scarring, partly because the ratio of TGF-β3 to TGF-β1 is much higher in utero. When researchers have applied TGF-β3 to adult wounds or scars in clinical studies, it has shown promise in reducing or preventing scar formation by promoting orderly collagen organization rather than accumulation. However, simply applying TGF-β3 topically comes with challenges: it’s a large protein that doesn’t easily penetrate skin, and its effects are temporary unless repeated. This gap between the biology and the practical therapy is why TGF-β3 remains primarily a research tool rather than an over-the-counter scar treatment, though pharmaceutical companies continue developing delivery systems to make it clinically viable.
How Dysregulation Transforms Normal Healing Into Excessive Scarring
The transition from normal wound healing to pathological scarring happens when the body fails to “turn off” TGF-β1 signaling after an acne lesion has healed. Several factors can trigger this dysregulation: genetic predisposition (some people’s fibroblasts are simply more responsive to TGF-β1), severity of the original acne lesion (deeper inflammations cause more tissue damage and longer TGF-β activation), and post-inflammatory hyperpigmentation or continued inflammation in the lesion area. In keloid-prone individuals, this dysregulation is even more extreme, causing scar tissue to grow beyond the original injury boundary.
A critical limitation of current dermatological practice is that we cannot easily predict who will develop problematic scars before they form. Two people with identical acne lesions may heal very differently—one with minimal scarring and another with significant indentation or raised tissue. This unpredictability makes scar prevention challenging; we can’t identify high-risk patients early enough to intervene during the active scarring phase. Once a scar is mature (typically after 12-18 months), the TGF-β dysregulation and collagen reorganization have stabilized, making it far harder to reverse.
Botulinum Toxin as a TGF-Beta Pathway Modulator
While botulinum toxin is well-known for reducing dynamic wrinkles by relaxing facial muscles, it also improves scar appearance through a less publicized mechanism: modulation of TGF-β signaling. By inhibiting muscle contraction at the scar edges, botulinum toxin reduces tension on the healing tissue. But more importantly, it concurrently suppresses inflammatory factors—interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)—while promoting orderly collagen deposition via reduced TGF-β pathway activation.
This means botulinum toxin doesn’t just relax muscles; it changes the chemical environment around the scar to favor better-organized collagen formation. In clinical practice, this makes botulinum toxin particularly useful for newer scars (less than 2 years old) where fibroblasts are still actively remodeling tissue. The combination of mechanical relaxation and biochemical modulation can noticeably soften scar appearance over 3-6 months. However, the effect is temporary—lasting 3-4 months before re-injection is needed—and it works best on scars where muscle contraction contributes to the appearance, such as scars near the eyes or mouth.
Pharmacological Intervention—Losartan and Beyond
Losartan, a medication traditionally used to treat high blood pressure, has emerged as a potential topical scar treatment because it directly inhibits the TGF-β/Smad signaling pathway. When applied as a cream to developing scars or keloids, losartan suppresses the pathological collagen accumulation by blocking TGF-β pathway activation in fibroblasts.
This represents a significant shift in scar treatment philosophy—moving from purely physical/mechanical approaches (microneedling, lasers, excision) to pharmacological intervention that targets the underlying molecular driver of scar formation. The research on losartan cream shows promise, but clinical adoption has been limited by manufacturing complexity and the need for more long-term safety data on topical application. As the field advances, we can expect additional TGF-β pathway inhibitors to enter clinical trials, potentially offering patients preventive options to use during the active scarring phase—transforming acne scar treatment from a cosmetic concern addressed years later into an early intervention applied while scars are still forming.
Conclusion
TGF-beta signaling, particularly through the TGF-β/Smad pathway, is the fundamental mechanism driving acne scar formation. Dysregulation of this pathway causes excessive collagen production, fibroblast proliferation, and loss of normal collagen remodeling—resulting in the indented, raised, or discolored scars that persist long after acne has cleared.
Understanding this biology has shifted scar treatment from purely physical approaches to targeted pharmacological interventions that address the root cause rather than just the surface appearance. The future of acne scar prevention likely lies in early intervention during the active healing phase, using treatments that modulate TGF-beta signaling before excessive collagen deposition becomes permanent. While existing options like botulinum toxin and losartan cream show promise, continued research into TGF-β3 delivery systems and dual-pathway inhibitors may eventually allow dermatologists to prevent acne scarring altogether—turning what is now an inevitable consequence of severe acne into a preventable complication.
